COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

被引:130
|
作者
Chi, Wei-Yu [1 ]
Li, Yen-Der [2 ]
Huang, Hsin-Che [3 ]
Chan, Timothy En Haw [4 ,5 ,6 ]
Chow, Sih-Yao [7 ]
Su, Jun-Han [2 ]
Ferrall, Louise [8 ]
Hung, Chien-Fu [8 ,9 ,10 ]
Wu, T-C [8 ,9 ,10 ,11 ,12 ]
机构
[1] Weill Cornell Med, Physiol Biophys & Syst Biol Grad Program, New York, NY USA
[2] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA
[3] Mem Sloan Kettering Canc Ctr, Triinst PhD Program Chem Biol, 1275 York Ave, New York, NY 10021 USA
[4] Max Planck Inst Immunobiol & Epigenet, Int Max Planck Res Sch Immunobiol Epigenet & Meta, Freiburg, Germany
[5] Univ Freiburg, Med Ctr, Dept Urol, Freiburg, Germany
[6] Univ Freiburg, Fac Biol, Freiburg, Germany
[7] EirGenix Inc, Downstream Proc Sci, Hsinchu, Taiwan
[8] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21218 USA
[9] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21218 USA
[10] Johns Hopkins Univ, Dept Obstet & Gynecol, Baltimore, MD 21218 USA
[11] Johns Hopkins Univ, Dept Microbiol & Immunol, Baltimore, MD 21218 USA
[12] Johns Hopkins Med Inst, CRB 2 Room 309,1550 Orleans St, Baltimore, MD 21231 USA
关键词
COVID-19; Vaccine; Immunity; Variant; SARS-CoV-2; NCOV-19; AZD1222; VACCINE; MESSENGER-RNA; CHADOX1; BNT162B2; SINGLE-BLIND; NEUTRALIZING ANTIBODY; OMICRON VARIANT; NON-INFERIORITY; UNITED-STATES; IMMUNOGENICITY;
D O I
10.1186/s12929-022-00853-8
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Coronavirus Disease 2019 (COVID-19) has been the most severe public health challenge in this century. Two years after its emergence, the rapid development and deployment of effective COVID-19 vaccines have successfully controlled this pandemic and greatly reduced the risk of severe illness and death associated with COVID-19. However, due to its ability to rapidly evolve, the SARS-CoV-2 virus may never be eradicated, and there are many important new topics to work on if we need to live with this virus for a long time. To this end, we hope to provide essential knowledge for researchers who work on the improvement of future COVID-19 vaccines. In this review, we provided an up-to-date summary for current COVID-19 vaccines, discussed the biological basis and clinical impact of SARS-CoV-2 variants and subvariants, and analyzed the effectiveness of various vaccine booster regimens against different SARS-CoV-2 strains. Additionally, we reviewed potential mechanisms of vaccine-induced severe adverse events, summarized current studies regarding immune correlates of protection, and finally, discussed the development of next-generation vaccines.
引用
收藏
页数:27
相关论文
共 50 条
  • [41] Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
    Gobbi, Federico
    Buonfrate, Dora
    Moro, Lucia
    Rodari, Paola
    Piubelli, Chiara
    Caldrer, Sara
    Riccetti, Silvia
    Sinigaglia, Alessandro
    Barzon, Luisa
    VIRUSES-BASEL, 2021, 13 (03):
  • [42] Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex
    Patone, Martina
    Mei, Xue W.
    Handunnetthi, Lahiru
    Dixon, Sharon
    Zaccardi, Francesco
    Shankar-Hari, Manu
    Watkinson, Peter
    Khunti, Kamlesh
    Harnden, Anthony
    Coupland, Carol A. C.
    Channon, Keith M.
    Mills, Nicholas L.
    Sheikh, Aziz
    Hippisley-Cox, Julia
    CIRCULATION, 2022, 146 (10) : 743 - 754
  • [43] Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
    Parums, Dinah, V
    MEDICAL SCIENCE MONITOR, 2021, 27
  • [44] An update on the impact of SARS-CoV-2 pandemic public awareness on cancer patients' COVID-19 vaccine compliance: Outcomes and recommendations
    Souan, Lina
    Sughayer, Maher A.
    Abu Alhowr, Maha
    Ammar, Khawlah
    Bader, Sara Al
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [45] An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations
    Kantarcioglu, Bulent
    Iqbal, Omer
    Lewis, Joseph
    Carter, Charles A.
    Singh, Meharvan
    Lievano, Fabio
    Ligocki, Mark
    Jeske, Walter
    Adiguzel, Cafer
    Gerotziafas, Grigoris T. T.
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [46] An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations
    Kantarcioglu, Bulent
    Iqbal, Omer
    Lewis, Joseph
    Carter, Charles A.
    Singh, Meharvan
    Lievano, Fabio
    Ligocki, Mark
    Jeske, Walter
    Adiguzel, Cafer
    Gerotziafas, Grigoris T.
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [47] Immune Response to SARS-CoV-2 Vaccine in 2 Men
    Gupta, Sudhir
    Su, Houfen
    Agrawal, Sudhanshu
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2022, 183 (03) : 350 - 359
  • [48] An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations
    Kantarcioglu, Bulent
    Iqbal, Omer
    Lewis, Joseph
    Carter, Charles A.
    Singh, Meharvan
    Lievano, Fabio
    Ligocki, Mark
    Jeske, Walter
    Adiguzel, Cafer
    Gerotziafas, Grigoris T.
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [49] Frequency of SARS-COV-2 infection and COVID-19 vaccine uptake and protection among Syrian refugees COVID-19 Vaccine among Syrian Refugees
    Altas, Zeynep Meva
    Sezerol, Mehmet Akif
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [50] SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects
    Boschi, Celine
    Scheim, David E.
    Bancod, Audrey
    Militello, Muriel
    Le Bideau, Marion
    Colson, Philippe
    Fantini, Jacques
    La Scola, Bernard
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)